Back

Direct delivery of Cas9 or base editor protein and guide RNA complex enables genome editing in the retina

Botto, C.; Pulman, J.; Malki, H.; Ren, D.; Oudin, P.; De Cian, A.; As, M.; Izabelle, C.; Saubamea, B.; Fouquet, S.; Robert, C.; El-Amraoui, A.; FISSON, S.; Concordet, J.-P.; Dalkara, D.

2023-10-17 bioengineering
10.1101/2023.10.16.562239 bioRxiv
Show abstract

Genome editing by CRISPR-Cas holds promise for the treatment of retinal dystrophies. For therapeutic gene editing, transient delivery of CRISPR- Cas9 is preferable to viral delivery which leads to long-term expression with potential adverse consequences. Successful delivery of Cas9 protein and its guide RNA as ribonucleoprotein (RNP) complexes has been reported in the retinal pigment epithelium in vivo but not into photoreceptors, the main target of retinal dystrophies. Here, we investigate the feasibility of direct RNP delivery to photoreceptors and RPE cells. We show that RNPs composed of Cas9 or adenine- base editor and guide RNA, without addition of any carrier compounds, induce gene editing in retinal cells at variable rates depending on the guide RNA efficiency and on the locus. But Cas9 RNP delivery at high concentrations leads to outer retinal toxicity indicating a need to improve delivery efficiency for future therapeutic use.

Matching journals

The top 3 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.